Pros | ![]() Lower expense ratio. ![]() Beats FD returns for both 3Y & 5Y duration. | ![]() Larger AUM within category. ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | ![]() 3Y returns in the bottom 25% of the category. | ![]() 5Y returns in the bottom 25% of the category. ![]() 3Y returns in the bottom 25% of the category. |
INDMoney rank | 5/8 | 7/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 7 Years | 12 Years | ||
Fund Size | 2908 Cr | 8737 Cr | ||
Min Investment | SIP ₹99 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.48% | 0.89% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 34 | 41 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (10.74%) Divi's Laboratories Ltd (8.02%) Glenmark Pharmaceuticals Ltd (7.24%) Aurobindo Pharma Ltd (6.41%) Cipla Ltd (6.11%) | Sun Pharmaceuticals Industries Ltd (12.22%) Divi's Laboratories Ltd (7.55%) Lupin Ltd (5.93%) Cipla Ltd (5.69%) Dr Reddy's Laboratories Ltd (5.69%) | ||
No of Sectors | 2 | 1 | ||
Top 3 Sectors | Health (98.66%) Basic Materials (1.34%) | Health (100%) | ||
Equity % | 99.63% | 99.45% | ||
Debt % | - | - | ||
P/E | 38.73 | 37.97 | ||
P/B | 5.56 | 6.05 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | -0.46% | -0.28% | ||
3-Month Return | 5% | 2.46% | ||
6-Month Return | 15.34% | 13.27% | ||
1-Year Return | 0.88% | 0.08% | ||
3-Year Return | 23.59% | 24.54% | ||
5-Year Return | 20.64% | 20.19% |
Sharpe | 0.94 | 1.06 | ||
Alpha | -1.4 | 0.66 | ||
Beta | 1 | 0.91 | ||
Standard Deviation | 16.38 | 15.05 | ||
Information Ratio | -0.61 | -0.24 |
Description | Mirae Asset Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Vrijesh Kasera | Sailesh Raj Bhan,Kinjal Desai |